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ABSTRACT - PURPOSE: The prominent ATP-binding cassette (ABC) transporters ABCB1, ABCC1, and 
ABCG2 are involved in substance transport across physiological barriers and therefore in drug absorption, 
distribution, and elimination. They also mediate multi-drug resistance in cancer cells. Different flavonoids 
are known to interfere with different ABC transporters. Here, the effect of the furanoflavonol karanjin, a 
potential drug with antiglycaemic, gastroprotective, antifungal, and antibacterial effects, was investigated on 
ABCB1, ABCC1, and ABCG2-mediated drug transport in comparison to the flavonoids apigenin, genistein, 
and naringenin. METHODS: Cells expressing the relevant transporters (ABCB1: UKF-NB-3ABCB1, UKF-
NB-3rVCR10; ABCC1: G62, PC-3rVCR20; ABCG2: UKF-NB-3ABCG2) were used in combination with 
specific fluorescent and cytotoxic ABC transporter substrates and ABC transporter inhibitors to study ABC 
transporter function. Moreover, the effects of the investigated flavonoids were determined on the ABC 
transporter ATPase activities. RESULTS: Karanjin interfered with drug efflux mediated by ABCB1, 
ABCC1, and ABCG2 and enhanced the ATPase activity of all three transporters. Moreover, karanjin exerted 
more pronounced effects than the control flavonoids apigenin, genistein, and naringenin on all three 
transporters. Most notably, karanjin interfered with ABCB1 at low concentrations being about 1µM. 
CONCLUSIONS: Taken together, these findings should be taken into account during further consideration 
of karanjin as a potential drug for different therapeutic indications. The effects on ABCB1, ABCC1, and 
ABCG2 may affect the pharmacokinetics of co-administered drugs. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
____________________________________________________________________
 
INTRODUCTION 
 
ATP binding cassette (ABC) transporters are 
ATP-dependent pumps that transport substances 
across biological membranes. They play 
important roles in the passage of drugs, 
xenobiotics, and food constituents through 
cellular and tissue barriers and consequently in 
their absorption, distribution, and excretion. 
Moreover, different ABC transporters are 
frequently found highly expressed on cancer cells 
playing an important role in cancer cell 
chemoresistance (1-4). 
Flavonoids are plant polyphenols known to be 
present in tea, vegetables, nuts, citrus fruits, and 
herbal products. They belong to the most 
frequently consumed natural products. Many 
flavonoids have been found to interfere with 
various ABC transporters (5,6). These effects are 
of interest for two different reasons: 1) flavonoids 
may interfere with the absorption, distribution, 
and excretion of drugs or xenobiotics through 
their effects on ABC transporters 2) a number of 
different flavonoids is under investigation as anti-
cancer agents and effects on ABC transporters are  
 
relevant for their anti-cancer activities, especially 
in combination with other anti-cancer drugs that 
interfere with ABC transporters and/or are ABC 
transporter substrates (5,6).  Moreover, many 
flavonoids are discussed as chemopreventive 
agents (7,8). 
Karanjin is a flavonoid isolated from karanja 
(Pongamia glabra Vent.) and other Pongamia 
species used as bio-insecticide and bio-pesticide 
(9-12). Moreover, karanjin has been reported to 
exert antiglycemic, gastroprotective, antifungal, 
and antibacterial effects (11-17) and to be very 
well tolerated in rats (17). 
Here, we demonstrate that karanjin interferes 
with the action of the ABC transporters ABCB1 
(also known as P-glycoprotein, the gene is also 
known as multi-drug resistance gene 1, MDR1), 
ABCC1 (also known as multi-drug resistance-
associated protein 1, MRP1), and ABCG2 (also 
known as breast cancer resistance protein 1, 
BCRP1). 
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This represents the first investigation of the 
effects of the drug candidate karanjin on these 
three major ABC transporters. Moreover, we 
show that karanjin exerts substantially enhanced 
effects on ABCB1 compared to apigenin, 
genistein, and narigenin, three flavonoids that 
were used as control compounds because they are 
known to interfere with ABC transporters. 
MATERIALS AND METHODS 
Drugs 
Karanjin was obtained from Indofine Chemical 
Company Inc. (Hillsborough, NJ, USA) via 
ABCR GmbH & Co. KG (Karlsruhe, Germany). 
Vincristine, verapamil, PGP-4008, NEM (N-
ethylmaleimide), and GS (reduced glutathione) 
were obtained from Sigma-Aldrich (Deisenhofen, 
Germany). Rhodamine 123, MK571, 
sulfasalazine, and 5-CFDA (5-Carboxyfluorescein 
diacetate) were purchased from Merck 
Biosciences (Darmstadt, Germany). Mitoxantrone 
was received from GRY Pharma (Kirchzarten, 
Germany). Ko 143 was purchased from TOCRIS 
Bioscence (Bristol, UK). BODIPY-FL-prazosine 
(BODIPY-prazosine) was obtained from 
Invitrogen GmbH (Frankfurt/Main, Germany). 
Cell lines 
The neuroblastoma cell line UKF-NB-3 was 
established from bone marrow metastasis of a 
stage IV neuroblastoma patient with MYCN-
amplification (18). ABCB1 -overexpressing 
(UKF-NB-3ABCB1, control cell line UKF-NB-3Cer2) 
or ABCG2-overexpressing (UKF-NB-3ABCG2, 
control cell line UKF-NB-3iG2) sub-lines of UKF-
NB-3 were established by lentiviral transduction 
with LeGO vectors encoding ABCB1, ABCG2, or 
corresponding control vectors, respectively. 
Vectors were derived using standard molecular 
cloning techniques as described before (19,20) 
(see also www.lentigo-vectors.de). UKF-NB-
3rVCR10 is a UKF-NB-3 sub-line characterised by 
high ABCB1 expression that was established by 
adaptation of UKF-NB-3 to growth in the 
presence of vincristine 10ng/ml (18,21). 
The glioblastoma cell line G62 (22) was 
obtained from Dr. Dorothee von Laer (Medical 
University, Innsbruck, Austria). Among ABC 
transporters investigated, it shows expression of 
ABCC1 and ABCG2 (Suppl. Figure 1). Using the 
ABCC1-specific fluorescence substrate 5-CFDA 
or vincristine, a cytotoxic drug transported by 
ABCC1 but not by ABCG2, G62 represents a 
suited model to study ABCC1 function. The 
MABCC1-specific ABC transporter inhibitor 
MK571 but not the ABCG2-specific inhibitor 
Ko143 or the ABCB1-specific inhibitor PGP-
4008 caused 5-CFDA accumulation in G62 cells 
and sensitised G62 cells to vincristine cytotoxicity 
(Suppl. Figure 1). 
All cell lines were propagated in IMDM 
supplemented with 10 % FBS, 100 IU/ml 
penicillin and 100 mg/ml streptomycin at 37°C. 
Cells were routinely tested for mycoplasma 
contamination. 
 
Viability assay 
Cell viability was tested by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye reduction assay after 120 h 
incubation, modified as described before (21). All 
experiments were performed at least in triplicate. 
 
Flow cytometry and investigation of efflux of 
ABC transporter substrates 
Antibodies directed against ABCB1 (Alexis 
Biochemicals via AXXORA Deutschland, 
Lörrach, Germany), ABCC1, or ABCG2 (both 
Kamiya Biomedical Company, Seattle, WA, 
USA), followed by secondary antibody labelled 
with Phycoerythrin (R&D, Wiesbaden, Germany) 
were used to detect protein expression by flow 
cytometry (FACSCalibur, BD Biosciences, 
Heidelberg, Germany). 
ABC transporter-mediated drug efflux and 
wash-out kinetics were determined as described 
before (20,21). To investigate ABCB1 -mediated 
substance efflux, cells were preincubated with 
different concentrations of karanjin for 30 min. 10 
µM verapamil was used as positive control for 
ABCB1 -mediated efflux. 0.1 µM rhodamine 123 
was added for another 30 min. Then, cell culture 
medium was removed, cells were washed three 
times with PBS, and fresh medium containing 
drugs was added. After another 45 min, cellular 
fluorescence was analysed by flow cytometry. 
Rhodamine 123 was detected at the FL1 channel. 
For wash out kinetic experiments, UKF-NB-
3ABCB1 cells were incubated for 1h with rhodamine 
123 0.1 µM together with different concentrations 
of karanjin or with verapamil 10 µM (positive 
control for that inhibits ABCB1 function). 
Subsequently, cells were washed, re-suspended in 
supplemented medium, and the cellular 
fluorescence was measured after different time 
points (t0, t5, t15, t30, t60, t120 minutes) by flow 
cytometry. 
To investigate ABCC1- or ABCG2-mediated 
efflux, the same procedures were carried out. For 
investigation of the influence of karanjin on 
ABCC1 function, G62 cells were used. 5-CFDA 
(detected at the FL1 channel) served as 
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fluorescent ABCC1 substrate and vincristine as 
cytotoxic ABCC1 substrate. 
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Figure 1. Interference of karanjin with P-glycoprotein 
(ABCB1) activity. A) Concentration-dependent 
influence of karanjin on rhodamine 123 (0.1 µM) 
fluorescence in UKF-NB-3ABCB1 cells, B) time kinetics 
of rhodamine 123 (0.1 µM) fluorescence in UKF-NB-
3ABCB1 cells in the presence of karanjin after a 60 min 
pre-incubation period with subsequent wash-out of 
extracellular rhodamine 123 and karanjin (control = 
rhodamine 123 incubation in the absence of drugs). C) 
ABCB1 ATPase activity in isolated membranes in the 
presence of karanjin (control = activity in the absence 
of drugs). Verapamil, a known ABCB1 substrate, was 
used for comparison. * P < 0.05 relative to non-treated 
controls. 
 
The ABCC1 inhibitor MK571 was used as control 
substance. For ABCG2, UKF-NB-3ABCG2 cells 
were used. BODIPY-prazosine served as 
fluorescent ABCG2 substrate (detected at the FL1 
channel). Mitoxantrone served as cytotoxic 
ABCG2 substrate. The ABCG2 inhibitor Ko143 
was used as control substance. 
Determination of ATPase activity 
The ATPase activities of ABCB1, ABCC1, and 
ABCG2 were determined using membrane 
preparations (ABCB1-Membran: BD Biosciences, 
Heidelberg, Germany; ABCC1- and ABCG2 
membranes: Solvo Biotechnology, Budapest, 
Hungary) and an established kit (BD Biosciences, 
Heidelberg, Germany) following the 
manufacturer’s instruction. 
 
STATISTICAL ANALYSIS 
 
Two groups were compared by t-test. More 
groups were compared by ANOVA with 
subsequent Student-Newman-Keuls test. 
 
RESULTS 
 
Influence of karanjin on ABCB1 activity 
Karanjin concentrations ≤ 40 µM increased 
accumulation of the fluorescent ABCB1 substrate 
rhodamine 123 in ABCB1-expressing UKF-NB-
3ABCB1 cells (but not in empty vector-transduced 
control UKF-NB-3Cer2 cells or non-transduced 
parental UKF-NB-3 cells that lack ABCB1 
expression, not shown) in a concentration-
dependent manner (Figure 1A). However, 
karanjin 40 µM did not affect ABCB1 expression 
(Suppl. Figure 2A).  
Next, we investigated the ABCB1 wash-out 
kinetics of karanjin. Cells were incubated with 
rhodamine 123 in the presence of karanjin 60 min. 
Subsequently, cells were washed and cellular 
fluorescence was monitored at different time 
points by flow cytometry. The wash-out of 
karanjin resulted in a fast decrease of rhodamine 
123 fluorescence (Figure 1B). Moreover, karanjin 
increased ABCB1 ATPase activity (Figure 1C). 
Next the influence of karanjin was investigated on 
toxicity exerted by the ABCB1 substrate 
vincristine in UKF-NB-3ABCB1 cells (Figure 2A). 
The effects were compared to those of apigenin, 
genistein, and naringenin that are flavonoids 
known to interfere with function of these ABC 
transporters (6,23-25). Karanjin 20µM caused the 
strongest sensitisation to vincristine resulting in 
an 85-fold decrease of the vincristine IC50 value 
whereas apigenin 20µM (5-fold), genistein 20µM  
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Figure 2. Influence of karanjin on cancer cell 
sensitivity to cytotoxic ABC transporter substrates in 
comparison to other flavonoids. A) Concentrations of 
vincristine (cytotoxic substrate of P-glycoprotein 
(ABCB1)) that decrease cell viability by 50% (IC50) in 
ABCB1-expressing UKF-NB-3ABCB1 cells in the 
presence of karanjin 20µM (cell viability in the 
absence of vincristine is 76.13 ± 9.52% relative to 
control), apigenin 20µM (73.27 ± 13.05%), genistein 
20µM (32.60 ± 8.09%), or naringenin 20µM (62.68 ± 
15.98%). B) Vincristine (cytotoxic substrate of 
ABCC1) IC50s in ABCC1-expressing G62 cells in the 
presence of karanjin 20µM (92.73 ± 3.94%), apigenin 
20µM (82.56 ± 7.64%), genistein 20µM (79.04 ± 
3.75%), or naringenin 20µM (84.13 ± 5.44%). C) 
Mitoxantrone (cytotoxic substrate of ABCG2) IC50s in 
ABCG2-expressing UKF-NB-3ABCG2 cells in the 
presence of karanjin 20µM (83.73 ± 15.22%), apigenin 
20µM (77.26 ± 12.63%), genistein 20µM (62.03 ± 
10.68%), or naringenin 20µM (64.82 ± 9.90%).* P < 
0.05 relative to non-treated controls. 
(2-fold), or naringenin 20µM (2-fold) exerted 
only moderate effects (Figure 2A). Similar 
relative changes in the effects on vincristine 
activity were detected when we used the 
investigated flavonoids at a concentration of 
10µM (Suppl. Table 1). 
Sensitisation of UKF-NB-3ABCB1 cells to 
vincristine by karanjin occured in a dose-
dependent manner with karanjin 1.25 µM still 
resulting in a statistically significant (2.5-fold) 
reduction of the vincristine IC50 (Suppl. Table 2). 
Similar results were obtained in UKF-NB-
3rVCR10 cells (Suppl. Table 2), a sub-line of 
UKF-NB-3 adapted to growth in the presence of 
vincristine 10ng/ml, that is characterised by high 
ABCB1 expression (18,21). The vincristine IC50s 
of the parental cell line UKF-NB-3 and the vector 
control UKF-NB-3Cer2 were not influenced by 
karanjin (Suppl. Table 2). 
 
Influence of karanjin on ABCC1 activity 
Karanjin increased accumulation of the 
fluorescent ABCC1 substrate 5-CFDA in 
ABCC1-expressing G62 cells in a concentration-
dependent manner (Figure 3A) but did not 
influence ABCC1 expression after incubation for 
up to 5 days (Suppl. Figure 2B). 
The determination of wash-out kinetics 
resulted in a rapid decline of 5-CFDA 
fluorescence in the presence of karanjin (Figure 
3B) and karanjin increased ABCC1 ATPase 
activity (Figure 3C). 
While genistein 20µM increased the 
vincristine IC50 in G62 cells (1.6-fold), apigenin 
20µM, naringenin 20µM, or karanjin 20µM 
reduced vincristine IC50s (Figure 2B). Karanjin 
20µM caused the strongest reduction (7-fold) 
followed by apigenin 20µM (5-fold) and 
naringenin 20µM (1.4-fold). Similar relative 
changes in the effects on vincristine activity were 
detected when we used the investigated 
flavonoids at a concentration of 10µM (Suppl. 
Table 1). 
Moreover, karanjin sensitised G62 cells and 
PC-3rVCR20 cells (another ABCC1 model, see 
(20,21)) to vincristine in a dose-dependent fashion 
(Suppl. Table 2). In both cell lines, karanjin 5µM 
was the lowest concentration that significantly 
reduced the vincristine IC50 (G62: 2.3-fold; PC-
3rVCR20: 1.8-fold). 
 
Influence of karanjin on ABCG2 activity 
Treatment of ABCG2-expressing UKF-NB-
3ABCG2 cells with karanjin in the presence of the 
fluorescent ABCG2 substrate BODIPY-prazosine 
resulted in a dose-dependent increase in cellular 
BODIPY-prazosine fluorescence (Figure 4A).  
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Figure 3. Interference of karanjin with ABCC1 
activity. A) Concentration-dependent influence of 
karanjin on 5-CFDA (0.2µM) fluorescence in G62 
cells, B) time kinetics of 5-CFDA (1µM) fluorescence 
in G62 cells in the presence of karanjin after a 60 min 
pre-incubation period with subsequent wash-out of 
extracellular 5-CFDA and karanjin (control = 5-CFDA 
incubation in the absence of drugs). C) ABCC1 
ATPase activity in isolated membranes in the presence 
of karanjin (control = activity in the absence of drugs). 
NEM-GS (a freshly prepared 1:1 mixture of NEM and 
GS), a known ABCC1 substrate, was used for 
comparison. * P < 0.05 relative to non-treated controls 
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Figure 4. Interference of karanjin with ABCG2 
activity. A) Concentration-dependent influence of 
karanjin on BODIPY-prazosine (0.2 µM) fluorescence 
in UKF-NB-3ABCG2 cells, B) time kinetics of BODIPY-
prazosine (1 µM) fluorescence in UKF-NB-3ABCG2 
cells in the presence of karanjin after a 60 min pre-
incubation period with subsequent wash-out of 
extracellular BODIPY-prazosine and karanjin (control 
= BODIPY-prazosine incubation in the absence of 
drugs). C) ABCG2 ATPase activity in isolated 
membranes in the presence of karanjin (control = 
activity in the absence of drugs). Sulfasalazine, a 
known ABCG2 substrate, was used for comparison. * 
P < 0.05 relative to non-treated controls 
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In contrast, karanjin did not affect BODIPY-
prazosine fluorescence in UKF-NB-3 cells or 
UKF-NB-3 cells transduced with the control 
vector (UKF-NB-3iG2, data not shown). In 
addition, karanjin did not influence ABCG2 
expression after incubation for 5 days (Suppl. 
Figure 2). 
The cellular BODIPY-prazosine fluorescence 
levels rapidly declined after wash-out of karajin in 
UKF-NB-3ABCG2 cells (Figure 4B) and karanjin 
increased ABCG2 ATPase activity (Figure 4C). 
Karanjin 20µM (217-fold), apigenin 20µM 
(59-fold), genistein (156-fold), as well as 
naringenin 20µM (27-fold) sensitised UKF-NB-
3ABCG2 cells to the cytotoxix ABCG2 substrate 
mitoxantrone (Figure 2C). Similar relative 
changes in the effects on mitoxantrone activity 
were detected when we used the investigated 
flavonoids at a concentration of 10µM (Suppl. 
Table 1). Moreover, karanjin sensitised UKF-NB-
3ABCG2 cells to mitoxantrone in a dose-dependent 
manner but did not affect mitoxantrone sensitivity 
of UKF-NB-3 cells or UKF-NB-3iG2 cells (Suppl. 
Table 2). 
 
DISCUSSION 
 
Flavonoids are ubiquitous constituents of our 
daily diet. Many pharmacological actions have 
been ascribed to this group of plant secondary 
metabolites (5-8). Many flavonoids are known to 
interfere with ABC transporter-mediated transport 
of drugs and xenobiotics (5,6). Here, we show 
that the flavonoid karanjin that has been reported 
to exert antiglycemic, gastroprotective, antifungal, 
and antibacterial effects and to be very well 
tolerated in rats (11-17) interferes with the 
cellular drug efflux through the major ABC 
transporters ABCB1, ABCC1, and ABCG2. This 
finding is of general importance for the 
assessment of karanjin as drug candidate for 
different diseases since ABC transporters play 
key roles during drug absorption, distribution, and 
excretion (2) and thus potential interactions 
between karanjin and other ABC transporter 
substrates (e.g. co-administered drugs, 
xenobiotics) will have to be considered. 
Moreover, ABC transporter inhibitors, 
particularly ABCB1 inhibitors, have been 
intensively investigated as anti-cancer drugs (1-
4,26). The use of first generation inhibitors such 
as verapamil or cyclosporine A (that were 
established drugs found to interfere with ABCB1) 
was limited by toxic (off-target) side effects (1-4). 
Later generations were more specific and acted as 
non-competitive ABC transporter inhibitors. 
Nevertheless, although some clinical phase I and 
II trials with ABC transporter inhibitors appeared 
to be encouraging, successful phase III trials are 
missing (1-4). Possibly, broad spectrum ABC 
transporter inhibitors might be needed since 
chemoresistant cancer (stem) cells express 
multiple ABC transporters and inhibition of one is 
not sufficient (27). Interestingly in this context, 
karanjin appears to exert stronger effects on 
ABCB1, ABCC1, as well as ABCG2 than the 
three flavonoids apigenin, genistein, and 
naringenin that are known to interfere with ABC 
transporter-mediated substance transport (6,23-
25) and that were therefore used for comparison. 
Notably, genistein protected G62 cells from 
vincristine-induced cytotoxicity. This might be 
due to cytoprotective activities including 
antioxidative and anti-apoptotic effects that have 
been attributed to flavonoids like genistein 
(28,29). Noteworthy in this context, karanjin 
consistently sensitised ABC transporter-
expressing tumour cells derived from three 
different entities (neuroblastoma, glioblastoma, 
prostate carcinoma) to varying anti-cancer drugs. 
Particularly, the effects of karanjin on 
ABCB1 function were substantially higher (85-
fold sensitisation of ABCB1-expressing UKF-
NB-3ABCB1 cells to the ABCB1 substrate 
vincristine by karanjin 20µM) than the effects 
mediated by the same concentration of apigenin, 
genistein, or naringenin that ranged between 2- 
and 5-fold sensitisation. Karanjin significantly 
sensitised UKF-NB-3ABCB1 cells to vincristine 
(2.5-fold) in a concentration as low as 1.25µM. 
Docking experiments did not indicate a 
significant difference in the binding affinities of 
karanjin, apigenin, genistein, naringenin to 
ABCB1 (Suppl. Figure 3). This suggests that the 
differences detected in the effects on ABCB1 
function between the investigated flavonoids may 
not be a consequence of differences in their 
binding to ABCB1. Hydrophobicity and a planar 
structure have been described to be important for 
flavonoid interaction with ABCB1 (30). Looking 
at the chemical structures of the investigated 
flavonoids (Figure 5), karanjin is the only 
substance lacking hydroxyl groups. Moreover, 
karanjin possesses in contrast to the other 
flavonoids a furan group (furanoflavonoid). 
Therefore, its pronounced effects on ABCB1 
appear to be in accordance with the established 
structure-activity-relationships. 
In conclusion, we show that the flavonoid 
karanjin interferes with substance transport 
mediated by the major ABC transporters ABCB1, 
ABCC1, and ABCG2. The effects exerted by 
karanjin appear to be more pronounced than those 
of apigenin, genistein, or naringenin, other 
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flavonoids with documented effects on ABC 
transporters that were used as control substances. 
Most notably, karanjin interfered with 
ABCB1-mediated drug efflux in very low 
micromolar concentrations. Due to the important 
roles of ABC transporters in drug absorption, 
distribution, and excretion these findings should 
be taken into account during further consideration 
of karanjin as a drug candidate exerting 
antiglycemic, gastroprotective, antifungal, and 
antibacterial effects. Moreover, broad spectrum 
ABC transporter inhibitors might have a role in 
anti-cancer therapies since high ABC transporter 
expression represents a central cancer cell 
chemoresistance mechanism. 
 
 
  
Figure 5. Chemical structures of the flavonoids 
karanjin, apigenin, genistein, and naringenin. 
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Suppl. Figure 1. G62 as ABCC1 model. A) expression 
of different ABC transporters on G62 cells determined 
by flow cytometry. Values are presented after 
subtraction of respective isotype controls. * P < 0.05 
relative to isotype control B) fluorescence of the 
ABCC1 substrate 5-CFDA 10µM in non-treated G62 
cells (control) or cells treated with MK571 10µM 
(ABCC1 inhibitor), PGP4008 2.5 µM (ABCB1 
inhibitor), or fumitremorgin C 10µM (ABCG2 
inhibitor). * P < 0.05 relative to control C) vincristine 
concentrations that reduce G62 cell viability by 50% 
(IC50). G62 cells were treated with vincristine alone 
(control) or with vincristine in the presence of MK571 
10µM, PGP4008 2.5 µM, or Ko143 10µM. * P < 0.05 
relative to control. 
 
 
A
AB
CB
1
ex
pre
ss
ion
 (r
fu)
10000
15000
20000
0 control
25000
5000
karanjin
B
AB
CC
1
ex
pre
ss
ion
 (r
fu)
1000
1500
2000
0 control
2500
500
karanjin
C
AB
CG
2
ex
pre
ss
ion
 (r
fu)
20000
30000
40000
0 control
50000
10000
karanjin   
 
Suppl. Figure 2. ABC transporter expression in the 
presence of karanjin. A) ABCB1 expression in non-
treated UKF-NB-3ABCB1 cells (control) or in UKF-NB-
3ABCB1 cells treated with karanjin 40µM for 5 days. B) 
ABCC1 expression in non-treated G62 cells (control) 
or in G62 cells treated with karanjin 40µM for 5 days. 
C) ABCG2 expression in non-treated UKF-NB-3ABCG2 
cells or in UKF-NB-3ABCG2 cells treated with karanjin 
40µM for 5 days.  
 
Suppl. Figure 3. ABCB1 docking studies of 
karanjin, apigenin, genistein, and naringenin. 
 
INTRODUCTION 
 
The docking study of karanjin, apigenin, genistein, and 
naringenin with ABCB1 was carried out using 3D 
structures of mouse Abcb1a. The x-ray structures of 
the mouse Abcb1a was downloaded from the protein 
data bank (PDB codes 3G60, 3G61 and 5GU) 
[http://www.rcsb.org]. It should be noted that two of 
the Abcb1a structures, 3G60, 3G61, are co-crystallised 
with stereo-isomers of cyclic hexapeptide inhibitors, 
cyclic-tris-(R)-valineselenazole (QZ59-RRR) and 
cyclic-tris-(S)-valineselenazole (QZ59-SSS). Docking 
was carried out using MOE software (MOE, version 
2011.10, Chemical Computing Group Inc. Montreal, 
Canada) as below. 
A Abcb1a structure was loaded into the software, 
where the crystal parameters were retained and all 
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atoms of the protein (Abcb1a) were protonated and 
titrated using default parameters of the software. To 
prepare the flavonoids for docking, atomic charge and 
energy minimisation calculation was performed using 
SCF optimisation (AM1 Hamiltonian). In MOE dock 
panel, the placement method was Triangle Matcher, 
scoring methodology was set to London dG as the first 
and the second scoring functions, refinement 
methodology was set to MMFF94 force field and, 
finally, 30 best scoring poses with the mean energies 
and backbone root mean square deviation (RMSD) 
were retained. The binding site was defined in MOE 
software as 1) QZ59-RRR binding site in 3G60 
protein, 2) verapamil binding site for 3G5U, 3) upper 
ligand binding site for QZ59-SSS in 3G61 and, 4)
 lower ligand binding site for QZ59-SSS in 
3G61. Default parameters were used for ligand 
interactions diagram with energy cut-off for hydrogen 
bonding and ionic interactions of -0.5 kcal/mol. 
Maximum distance for non-bonded atoms was 4.5 
angstrom. 
 
RESULTS 
 
Docking energies of the top scoring poses for 
interaction with four Abcb1a structure/binding site has 
been presented in Table 1. 
Table 1 shows that interactions are better with the 
binding site of QZ59-RRR in 3G60 structure. Table 2 
shows the scores of the second and third best docking 
poses with this binding site and the RMSD values of 
the top poses. The lowest calculated docking energies 
are presented in Table 2. 
Table 2. Protein interaction energies (kcal/mol) of 
four top poses of docking Abcb1a with flavonoids and 
the lowest RMSD values between the first and second 
poses for karanjin and naringenin, and between the 
third and fourth poses for apigenin and genistein. 
Table 3 shows the most important residues 
involved in the flavonoid-Abcb1a interaction 
according to the 2D-ligand interaction diagram of the 
top pose in ligand-enzyme docking. It must be noted 
that Phe 71, Met 68, Phe 974 are less important in the 
interaction compared to other residues in in the table. 
DISCUSSION  
 
All the flavonoids here apart from karanjin contain two 
hydroxyl groups in the A ring at positions 5 and 7, and 
in addition there is a hydroxyl group present in ring C. 
Hydroxyl groups can decrease the lipophilicity while it 
is a known fact that ABCB1 preference is for lipophilic 
compounds (Omote et al, 2006; Gatlik-Landwojtowicz 
et al, 2006; Gottesman et al, 1993). The yellow colour 
on the surface of the binding cavity in Abcb1a in 
Figure 1 indicates hydrophobic properties of the 
surface and it could be appropriate match with the 
hydrophobic rings of the flavonoids. 
All four flavonoids tested in this study have shown 
good affinities for the active site of receptor (Table 1). 
Docking energies of Table 1 shows that apigenin has 
the highest affinity to Abcb1a among the tested 
flavonoids. Previous in vivo studies by Conseil et al. 
also show that flavones like apigenin bind more 
strongly to ABCB1 than flavanones such as naringenin 
or isoflavones such as genistien. On the other hand, 
they show that highly hydrophilic flavonoid, rutin, has 
a very low affinity interaction with ABCB1 (Conseil et 
al, 1998). 
The residues Phe 724, Phe 332, Val 978, Phe 728, 
Tyr 303 in all four flavonoids are appointed as the key 
residues contributing to the affinity energy of the 
complexes studied. All complexes have shown 
relatively strong bonds with ring A. Furthermore, for 
apigenin and naringenin the interaction included strong 
hydrogen bonds and this could be the reason for higher 
docking energy. Broccatelli and his colleges previously 
report importance of hydrogen bonding in the 
interaction of flavonoid with ABCB1 (Broccatelli et al. 
2011).  
Three of the residues which bind to flavonoids in 
this study, are also the main residues in co-crystallized 
structure and docked models of P-gp for binding to 
QZ59-RRR.These are Phe 728, Phe 974 and Val 978. 
In this report we have shown that docking method 
is able to predict the binding of a small group of 
flavonoids and have provided good understanding of 
the interaction between the receptor (ABCB1) and 
inhibitors. 
 
Table 1. Top pose docking scores for flavonoids binding to Abcb1a. 
          
Flavonoids 
Abcb1a structure used for docking 
3G60 (RRR) 3G5U(using verapamil 
binding site) 
3G61 using Upper 
QZ59-SSS (Smaller) 
3G61 using  
Upper QZ59-SSS (Bigger) 
Karanjin -10.36 -7.15 -8.92 -7.58 
Apigenin -12.98 -10.20 -10.55 -9.98 
Genistein -10.88 -9.30 -10.54 -8.63 
Naringenin -12.43 -9.47 -10.48 -8.96 
 
 
Table 2. 
Flavonoids Docking energy of top four scoring poses (left to right) RMSD (Å) 
Karanjin -10.36 -10.19 -10.16 -10.06 2.15 
Apigenin -12.98 -11.83 -11.76 -11.13 2.68 
Genistein -10.88 -10.38 -10.37 -10.28 2.90 
Naringenin -12.43 -12.18 -11.87 -11.63 2.16 
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Table 3. Most important residues for docking of karanjin, apigenin, genistein and naringenin. 
Flavonoids Interacting and implying residues in first and second poses 
Karanjin Phe 724, Phe 332, Val 978, Phe 728, Tyr 303, Phe 71, Met 68, Phe 974 
Apigenin Phe 724, Phe 332, Val 978, Phe 728, Tyr 303, Phe 71, Phe 974 
Genistein Phe 724, Phe 332, Val 978, Phe 728, Tyr 303, Phe 71, Phe 974 
Naringenin Phe 724, Phe 332, Val 978, Phe 728, Tyr 303, Phe 71, Phe 974 
 
 
 Figure 1. 2D Ligand interaction diagrams for the top and the second top pose for docking karanjin, apigenin, 
naringenin and genistein into the binding site of the mouse Abcb1a (3G60) using MOE software; the polar and non-
polar amino-acids are shown in pink and green circles; hydrogen bonding is indicated by green dotted arrows; 
proximity contour are dotted lines surrounding the ligand and indicate the shape of the binding site and available space 
to the more outward-facing parts of the ligand; solvent exposure zone for the ligands have been indicated by violaceous 
areola (for example in benzofuran and chromene in karanjin). 
 
 
REFERENCES 
 
1. Aller S., Yu J.,  Ward A., Weng Y., Chittaboina 
S.,  Zhuo R., Harrell P., Trinh Y., Zhang Q., 
Urbatsch I., Chang G. 2009. Structure of P-
Glycoprotein Reveals a Molecular Basis for Poly-
Specific Drug Binding. Science. Vol. 323(5922) 
1718-1722. 
2. Ambudkar S.V., Kimchi-Sarfaty C, Sauna Z.E., 
Gottesman M.M. 2003. P-glycoprotein: from 
genomics to mechanism. Oncogene. 22(47):7468-
85. 
3. Andersen. Ø. M., Markham K.R. 2006. 
Flavonoids, Chemistry, biochemistry and 
applications. Chapter 9. Flavonoid-Protein 
Interactions. Taylor and Francis Group, LLC. 
USA.  
J Pharm Pharm Sci (www.cspsCanada.org) 17(1) 92 - 105, 2014 
 
103 
4. Barnes K.M., Dickstein B., Cutler G.B., Fojo T., 
Bates S.E. 1996. Steroid transport, accumulation, 
and antagonism of P-Glycoprotein in multidrug-
resistant cells. Biochemistry. 35, 4820-4827. 
5. Bois F., Beney C., Boumendjel A., Mariotte A.M., 
Conseil G., Di Pietro A. 1998. Halogenated 
chalcones with high-affinity binding to P-
glycoprotein: potential modulators of multidrug 
resistance. J Med Chem. 8, 41(21):4161-4. 
6. Boumendjel A., Bois F., Beney C., Mariotte A.M., 
Conseil G., Di Pietro A. 2001. B-ring substituted 
5,7-dihydroxyflavonols with high-affinity binding 
to P-glycoprotein responsible for cell multidrug 
resistance. Bioorg Med Chem Lett. 8,11(1):75-7. 
7. Boumendjel A., Di Pietro A., Dumontet C., Barron 
D. 2002. Recent advances in the discovery of 
flavonoids and analogs with high-affinity binding 
to P-glycoprotein responsible for cancer cell 
multidrug resistance. Med Res Rev.22(5), 512-29. 
8. Broccatelli F., Carosati E., Neri A., Frosini M, 
Goracci L, Oprea T.I., Cruciania G. 2011. A 
Novel Approach for Predicting P-glycoprotein 
(ABCB1) Inhibition Using Molecular Interaction 
Fields. J Med Chem. 54(6): 1740–1751.  
9. Castro A.F., Altenberg G.A. 1997. Inhibition of 
drug transport by genistein in multidrug-resistant 
cells expressing P-glycoprotein. Biochem 
Pharmacol. 10;53(1):89-93. 
10. Comte G., Daskiewicz J.B., Bayet C., Conseil G., 
Viornery-Vanier A., Dumontet C., Di Pietro A., 
Barron D. 2001. C-Isoprenylation of flavonoids 
enhances binding affinity toward P-glycoprotein 
and modulation of cancer cell chemoresistance. J 
Med Chem. 1;44(5):763-8. 
11. Conseil G., Baubichon-Cortay H., Dayan G., Jault 
J.M., Barron D., Di Pietro A. 1998. Flavonoids: a 
class of modulators with bifunctional interactions 
at vicinal ATP-and steroid-binding sites on mouse 
P-glycoprotein. Proc Natl Acad Sci USA. 95, 
9831-6. 
12. de Wet H., McIntosh DB., Conseil G.,Baubichon-
Cortay H., Krell T., Jault J.M., et al. 2001. 
Sequence Requirements of the ATP-Binding Site 
within the C-Terminal Nucleotide-Binding 
Domain of Mouse P-Glycoprotein: Structure-
Activity Relationships for flavonoid binding. 
Biochemistry. 40, 10382-91. 
13. Ekins S., Kim R.B., Leake B.F., Dantzig A.H., 
Schuetz E.G., Lan L.B., Yasuda K., Shepard R.L., 
Winter M.A., Schuetz J.D., Wikel J.H., Wrighton 
S.A. 2002. Three-dimensional quantitative 
structure-activity relationships of inhibitors of P-
glycoprotein. Molecular Pharmacology. 61, 964-
973. 
14. Gatlik-Landwojtowicz E, Äänismaa P, Seelig A. 
2006. Quantification and characterization of P-
glycoprotein–substrate interactions. Biochemistry. 
45:3020–32. 
15. Gottesman M.M., Pastan I. 1993. Biochemistry of 
multidrug resistance mediated by the multidrug 
transporter. Annu Rev Biochem. 62:385–427. 
16. Gutmann D, Ward A, Urbatsch I, Chang G, Veen 
H. 2010. Understanding polyspecificity of 
multidrug ABC transporters: closing in on the 
gaps in ABCB1. Trends in biochemical sciences. 
Volume 35 (1), 36-42. 
17. Jain S., Sareen V., Narula A. 1993. Oestrogenic 
and pregnancy interceptomy efficiency of a 
flavonoid mixture from grangea-maderaspatana 
poir (Artemisia maderaspatana) in the mouse. 
Phytother Res. 7. 381383. 
18. Jodoin J., Demeule M., Beliveau R. Inhibition of 
the multidrug resistance P-glycoprotein activity by 
green tea polyphenols. Biochim Biophys Acta. 
30;1542(1-3):149-59. 
19. Manthey J.A. 2000. Biological properties of 
flavonoids pertaining to inflammation. 
Microcirculation. 7, S29-34. 
20. Matsson P., Pedersen J.M., Norinder U., 
Bergström C.A.S., Artursson P. 2009. 
Identification of novel specific and general 
inhibitors of the three major human ATP-binding 
cassette transporters P-gp, BCRP, and MRP2 
among registered drugs. Pharmaceutical Research, 
Vol 26(8) 1816-1831. 
21. Mitcher L. A., Tekkepalli H., Waner P.B.B., Kuo 
S., Kuo S., Shanhel D.M., Stewart G. 1982. 
Naringenin, apigenin and genistein are weak 
estrogens, which bind to the estrogen receptor and 
elicit estrogen-induced response. Antimutatagenic 
and anticarcinogenic effects. Mutant Res. 267. 
229-241. 
22. Omote H, Al-Shawi MK. 2006. Interaction of 
transported drugs with the lipid bilayer and P-
glycoprotein through a solvation exchange 
mechanism. Biophys J. 90:4046–59. 
23. Rancon S, Chaboud A, Darbour N, Comte G, 
Bayet C, Simon PN, Raynaud J, Di Pietro A, 
Cabalion P, Barron D. 2001. Natural and synthetic 
benzophenones: interaction with the cytosolic 
binding domain of P-glycoprotein. 
Phytochemistry. 57(4):553-7. 
24. Singh P., Jain S., Bhala M., Goyal R.B., 
Jayaprokash D., Lohiya N.K. 1990. Wagonin, 5,7-
dihydroxy-8-methoxy-flavone as oestrogenic and 
anti-implantational agent in the rat. Phytother Res. 
4. 86-89. 
25. Spencer J. P. E. Flavonoids: modulators of brain 
function? 2008. British Journal of Nutrition 99, 
ES60–77. 
26. Squadrito F., Altavilla D., Squadrito G., Saitta A., 
Cucinotta D., Minutoli L., Deodato B., Ferlito M., 
Campo G.m., Bova A., Caputi A.P. 2000. 
Genistein supplementation and estrogen 
replacement therapy improve endothelial 
dysfunction induced by ovariectomy in rats. 
Cardiovasc Res. 45. 454-462. 
27. Wang R.B., Kuo C.L., Lien L.L., Lien E.J. 2003. 
Structure-activity relationship: analyses of p-
glycoprotein substrates and inhibitors. Journal of 
clinical pharmacy and therapeutics. 28. 203-228. 
28. Zhang S., Morris M.E. 2003. Effects of the 
flavonoids biochanin A, morin, phloretin, and 
silymarin on P-glycoprotein-mediated transport. J 
Pharmacol Exp Ther. 304(3):1258-67. 
J Pharm Pharm Sci (www.cspsCanada.org) 17(1) 92 - 105, 2014 
 
104 
Suppl. Table 1 
UKF-NB-3ABCB1
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 77.57 ± 10.11 7.61 ± 0.83 1.33 ± 0.19* 5.72
in the presence of apigenin
apigenin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 80.50 ± 10.11 7.61 ± 0.83 3.57 ± 0.65* 2.13
in the presence of genistein
genistein Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 59.77 ± 11.93 7.61 ± 0.83 4.67 ± 0.91* 1.63
in the presence of naringenin
apigenin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 65.75 ± 8.29 7.61 ± 0.83 4.48 ± 0.80* 1.70
in the presence of PGP4008
PGP4008** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
2.5 80.39 ± 10.74 7.61 ± 0.83 0.10 ± 0.02* 76.10
* P < 0.05 relative to vincristine alone
** Specific P-glycoprotein inhibitor serving as control   
G62
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 93.81 ± 6.17 2.72 ± 0.35 0.57 ± 0.12* 4.77
in the presence of apigenin
apigenin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 87.51 ± 19.16 2.72 ± 0.35 1.24 ± 0.43* 2.19
in the presence of genistein
genistein Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 85.17 ± 12.42 2.72 ± 0.35 3.35 ± 0.62 0.81
in the presence of naringenin
naringenin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 91.05 ± 8.29 2.72 ± 0.35 2.69 ± 0.74 1.01
in the presence of MK571
MK571** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 99.47 ± 2.84 2.72 ± 0.35 0.76 ± 0.11* 3.58
* P < 0.05 relative to vincristine alone
** Specific MRP1 inhibitor serving as control   
UKF-NB-3ABCG2
in the presence of karanjin
karanjin Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 88.03 ± 16.05 49.47 ± 10.60 1.50 ± 0.21* 32.98
in the presence of apigenin
apigenin Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 83.39 ± 14.36 49.47 ± 10.60 2.89 ± 0.83* 17.11
in the presence of genistein
genistein Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 71.11 ± 16.84 49.47 ± 10.60 2.14 ± 0.53* 23.11
in the presence of naringenin
naringenin Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 88.17 ± 15.54 49.47 ± 10.60 7.54 ± 1.21* 6.56
in the presence of Ko143
Ko143** Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 89.01 ± 12.14 49.47 ± 10.60 0.34 ± 0.06* 145.50
* P < 0.05 relative to mitoxantrone alone
** Specific BCRP1 inhibitor serving as control  Suppl. Table 2 
 
 
UKF-NB-3ABCB1
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.625 100.01 ± 10.83 7.61 ± 0.83 6.90 ± 1.12 1.10
1.25 87.47 ± 12.25 7.61 ± 0.83 3.03 ± 0.40* 2.51
2.5 82.52 ± 17.14 7.61 ± 0.83 2.16 ± 0.36* 3.52
5 84.88 ± 9.19 7.61 ± 0.83 1.94 ± 0.26* 3.92
10 77.57 ± 10.11 7.61 ± 0.83 1.33 ± 0.19* 5.72
20 76.13 ± 9.52 7.61 ± 0.83 0.09 ± 0.03* 84.56
40 62.24 ± 6.01 7.61 ± 0.83 0.05 ± 0.01* 152.20
in the presence of PGP4008
PGP4008** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
2.5 80.39 ± 10.74 7.61 ± 0.83 0.10 ± 0.02* 76.10
* P < 0.05 relative to vincristine alone
** Specific ABCB1 inhibitor serving as control   
 
UKF-NB-3
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.625 99.17 ± 4.26 0.14 ± 0.03 0.14 ± 0.04 1.00
1.25 96.00 ± 12.16 0.14 ± 0.03 0.13 ± 0.04 1.08
2.5 98.69 ± 12.09 0.14 ± 0.03 0.11 ± 0.03 1.27
5 95.22 ± 9.21 0.14 ± 0.03 0.11 ± 0.04 1.27
10 70.63 ± 10.82 0.14 ± 0.03 0.12 ± 0.03 1.17
20 64.01 ± 8.83 0.14 ± 0.03 0.10 ± 0.03 1.40
40 60.13 ± 9.45 0.14 ± 0.03 0.10 ± 0.05 1.40
in the presence of PGP4008
PGP4008** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
2.5 72.55 ± 15.90 0.14 ± 0.03 0.09 ± 0.05 1.56
* P < 0.05 relative to vincristine alone
** Specific ABCB1 inhibitor serving as control   
 
UKF-NB-3Cer2
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.625 86.33 ± 14.21 0.46 ± 0.19 0.63 ± 0.07 0.73
1.25 82.69 ± 20.09 0.46 ± 0.19 0.47 ± 0.04 0.98
2.5 79.93 ± 22.98 0.46 ± 0.19 0.38 ± 0.10 1.21
5 76.74 ± 12.80 0.46 ± 0.19 0.37 ± 0.11 1.24
10 75.02 ± 11.85 0.46 ± 0.19 0.35 ± 0.15 1.31
20 73.22 ± 9.19 0.46 ± 0.19 0.35 ± 0.12 1.31
40 71.39 ± 17.19 0.46 ± 0.19 0.33 ± 0.10 1.39
in the presence of PGP4008
PGP4008** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
2.5 74.62 ± 11.13 0.46 ± 0.19 0.40 ± 0.08 1.15
* P < 0.05 relative to vincristine alone
** Specific ABCB1 inhibitor serving as control  Cont’d … 
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UKF-NB-3rVCR10
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.625 105.63 ± 9.17 56.82 ± 7.04 48.12 ± 9.65 1.18
1.25 94.58 ± 6.72 56.82 ± 7.04 22.47 ± 2.33* 2.53
2.5 102.93 ± 11.96 56.82 ± 7.04 18.23 ± 0.96* 3.11
5 97.22 ± 8.54 56.82 ± 7.04 10.71 ± 1.09* 5.31
10 90.49 ± 7.69 56.82 ± 7.04 5.89 ± 0.80* 9.65
20 89.61 ± 11.43 56.82 ± 7.04 0.70 ± 0.16* 81.17
40 68.98 ± 10.84 56.82 ± 7.04 0.52 ± 0.03* 109.27
in the presence of PGP4008
PGP4008** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
2.5 86.50 ± 12.64 56.82 ± 7.04 1.01 ± 0.16* 56.26
* P < 0.05 relative to vincristine alone
** Specific ABCB1 inhibitor serving as control   
G62
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.625 97.42 ± 2.00 2.72 ± 0.35 2.67 ± 0.21 1.02
1.25 96.71 ± 5.57 2.72 ± 0.35 2.83 ± 0.27 0.96
2.5 93.69 ± 4.00 2.72 ± 0.35 2.51 ± 0.52 1.08
5 95.16 ± 5.02 2.72 ± 0.35 1.16 ± 0.10* 2.34
10 93.81 ± 6.17 2.72 ± 0.35 0.57 ± 0.12* 4.77
20 92.73 ± 3.94 2.72 ± 0.35 0.37 ± 0.04* 7.35
40 66.82 ± 5.62 2.72 ± 0.35 0.36 ± 0.16* 7.56
in the presence of MK571
MK571** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 99.47 ± 2.84 2.72 ± 0.35 0.76 ± 0.11* 3.58
* P < 0.05 relative to vincristine alone
** Specific ABCC1 inhibitor serving as control   
 
PC3rVCR20
in the presence of karanjin
karanjin Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.625 101.12 ± 2.72 31.06 ± 4.87 30.68 ± 1.81 1.01
1.25 97.42 ± 3.59 31.06 ± 4.87 29.37 ± 1.30 1.06
2.5 104.00 ± 10.00 31.06 ± 4.87 25.89 ± 2.62 1.20
5 102.50 ± 12.50 31.06 ± 4.87 17.02 ± 1.57* 1.82
10 100.30 ± 2.71 31.06 ± 4.87 11.75 ± 0.91* 2.64
20 98.98 ± 4.03 31.06 ± 4.87 5.61 ± 1.83* 5.54
40 53.21 ± 5.98 31.06 ± 4.87 2.46 ± 0.60* 12.63
in the presence of MK571
MK571** Cell viability IC50 vincristine IC50 vincristine fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 115.00 ± 7.00 31.06 ± 4.87 8.01 ± 2.03* 3.88
* P < 0.05 relative to vincristine alone
** Specific ABCC1 inhibitor serving as control   
 
 
 
 
UKF-NB-3ABCG2
in the presence of karanjin
karanjin Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.15625 103.45 ± 11.92 49.47 ± 10.60 39.91 ± 6.76 1.24
0.3125 100.62 ± 12.00 49.47 ± 10.60 23.22 ± 4.69* 2.13
0.625 98.13 ± 10.01 49.47 ± 10.60 10.74 ± 1.21* 4.61
1.25 91.95 ± 7.88 49.47 ± 10.60 5.49 ± 0.72* 9.01
2.5 78.97 ± 14.62 49.47 ± 10.60 4.56 ± 0.99* 10.85
5 86.32 ± 8.91 49.47 ± 10.60 3.53 ± 0.66* 14.01
10 88.03 ± 16.05 49.47 ± 10.60 1.50 ± 0.21* 32.98
20 83.73 ± 15.22 49.47 ± 10.60 0.23 ± 0.02* 216.98
40 64.31 ± 11.18 49.47 ± 10.60 0.07 ± 0.03* 706.71
in the presence of Ko143
Ko143** Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 89.01 ± 12.14 49.47 ± 10.60 0.34 ± 0.06* 145.50
* P < 0.05 relative to mitoxantrone alone
** Specific ABCG2 inhibitor serving as control   
 
UKF-NB-3
in the presence of karanjin
karanjin Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.15625 103.33 ± 8.37 0.18 ± 0.04 0.15 ± 0.02 1.20
0.3125 105.72 ± 9.00 0.18 ± 0.04 0.20 ± 0.06 0.90
0.625 99.16 ± 9.75 0.18 ± 0.04 0.20 ± 0.03 0.90
1.25 100.62 ± 12.93 0.18 ± 0.04 0.15 ± 0.05 1.20
2.5 98.91 ± 11.39 0.18 ± 0.04 0.16 ± 0.02 1.13
5 86.12 ± 15.19 0.18 ± 0.04 0.17 ± 0.03 1.06
10 77.72 ± 9.94 0.18 ± 0.04 0.15 ± 0.04 1.20
20 75.76 ± 10.44 0.18 ± 0.04 0.15 ± 0.02 1.20
40 70.35 ± 8.25 0.18 ± 0.04 0.16 ± 0.03 1.13
in the presence of Ko143
Ko143* Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 87.59 ± 7.99 0.18 ± 0.04 0.15 ± 0.04 1.20
* Specific ABCG2 inhibitor serving as control   
 
UKF-NB-3iG2
in the presence of karanjin
karanjin Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
0.15625 106.88 ± 8.39 0.19 ± 0.04 0.19 ± 0.03 1.00
0.3125 98.98 ± 11.00 0.19 ± 0.04 0.21 ± 0.04 0.90
0.625 94.57 ± 8.25 0.19 ± 0.04 0.19 ± 0.03 1.00
1.25 101.01 ± 10.82 0.19 ± 0.04 0.14 ± 0.04 1.36
2.5 104.84 ± 7.73 0.19 ± 0.04 0.17 ± 0.02 1.12
5 95.61 ± 12.21 0.19 ± 0.04 0.20 ± 0.03 0.95
10 91.38 ± 10.71 0.19 ± 0.04 0.19 ± 0.02 1.00
20 85.11 ± 9.98 0.19 ± 0.04 0.17 ± 0.05 1.12
40 82.04 ± 8.20 0.19 ± 0.04 0.17 ± 0.04 1.12
in the presence of Ko143
Ko143* Cell viability IC50 mitoxantrone IC50 mitoxantrone fold sensitisation
(µM) (% control) (ng/ml) (ng/ml)
10 80.32 ± 15.09 0.19 ± 0.04 0.16 ± 0.04 1.19
* Specific ABCG2 inhibitor serving as control
 
*** 
